• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but...

cafead

Administrator
Staff member
  • cafead   Jan 11, 2022 at 11:32: AM
via Andrew Obenshain officially took over as bluebird bio’s CEO when the company split into two back in November. But there’s one item from his prior desk that's still on his mind: the removal of Zynteglo from the European market.

article source
 

<